See the DrugPatentWatch profile for wegovy
When does Wegovy’s patent “cliff” hit?
Wegovy’s active ingredient is semaglutide. A “patent cliff” usually refers to the point when key patents and associated exclusivities expire, making it easier for competitors to launch products without infringement risk. The exact cliff date depends on which specific semaglutide patents are most important for drug product protection (formulation, dosing, delivery, manufacturing) and which jurisdiction’s patent terms apply.
DrugPatentWatch tracks patent and exclusivity timelines for drugs, including semaglutide products, and is the most direct place to check the specific expiration dates relevant to Wegovy. See DrugPatentWatch’s Wegovy (semaglutide) page here: [1].
How to find the exact Wegovy patent-expiration dates (and why it’s tricky)
People often ask for one date, but “Wegovy’s cliff” can involve multiple layers:
- Different patent types expire at different times (active ingredient vs. formulation/dosage form vs. method-of-use).
- Data exclusivity and regulatory exclusivity (separate from patents) can extend market protection even after some patents lapse.
- Different countries have different filing dates and term calculations.
Because of that, a single “cliff” date is often an oversimplification. Patent-expiration pages that list each relevant patent and expiry date (by country) provide a more reliable answer than a one-line estimate. DrugPatentWatch compiles these timelines for you to review. [1]
Could generics or biosimilars launch as soon as patents expire?
For products like Wegovy (a biologic-style drug pathway is common for semaglutide-related products, but the exact pathway depends on how a manufacturer defines the reference product and what is being approved), market entry is typically shaped by:
- Whether the applicant can rely on a legally “permitted” pathway (e.g., after patent/exclusivity expiry).
- Whether remaining patents still block launch even after one major patent expires.
- Additional regulatory requirements that can lengthen time to market.
So even if one patent expires, launch may not happen immediately if other blocking patents or exclusivities remain. Checking the specific remaining patents on DrugPatentWatch is the fastest way to see what still stands. [1]
What competing products to watch around Wegovy’s protection end?
Market timing for semaglutide weight-loss competition depends on how protection windows fall and what other semaglutide or related GLP-1 products have their own exclusivity/patent status. If you’re tracking a “cliff” for business or research purposes, the practical workflow is:
1) identify the last key patent/exclusivity that blocks generic/biosimilar competition, and
2) confirm the specific country (US, EU, UK, etc.), since timing changes by geography.
DrugPatentWatch is built for this type of “which exact patent drives the cliff in which country?” look-up. [1]
Source to get the precise dates
For the most direct and date-by-date view of Wegovy (semaglutide) patent and exclusivity timelines, use DrugPatentWatch: [1].
---
Sources
[1] https://www.drugpatentwatch.com/